Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (37 ops.)
Latest filing published 18 Sept 2026 for CRESCENT BIOPHARMA, INC., €11k.
Filing timeline
BuySaleJonathan McNeill
Insider track record
Disclosed buys
0
Disclosed sells
37
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jonathan McNeill: trading record in brief
This profile gathers the share dealings of Jonathan McNeill across 2 companies, led by Dyne Therapeutics, Inc. and Crescent Biopharma, Inc. We count 55 filings; the first trade dates from 17 September 2020 and the latest from 18 September 2026.
No open-market purchase appears, only 37 sales worth €5.6M. Besides market trades, the filings include 6 share grants and 9 option exercises. Since January 2026: no purchases and 3 sales on the market.
Most recently, on 18 September 2026, the filings show an open-market sale worth €56k in Crescent Biopharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Jonathan McNeill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations27 total
731 shares@ US$17.90Ordinary SharesSEC:0001628280-26-062700:0
3,839 shares@ US$16.71Ordinary SharesSEC:0001628280-26-062700:1
20,549 sharesOrdinary SharesSEC:0001628280-26-044885:0
19,507 sharesOrdinary SharesSEC:0001628280-25-057678:0
2,400 shares@ US$45.017.5% of flowCommon StockSEC:0000950170-24-099127:0
1,823 shares@ US$31.344.1% of flowCommon StockSEC:0000950170-24-072151:0
2,279 shares@ US$28.204.5% of flowCommon StockSEC:0000950170-24-062075:0
86,159 shares@ US$5.5433.5% of flowCommon StockSEC:0000950170-24-030484:0
2,434 shares@ US$25.854.4% of flowCommon StockSEC:0000950170-24-029607:0
4,268 shares@ US$0.730.2% of flowCommon StockSEC:0000950170-24-024299:0
20,000 shares@ US$0.731.0% of flowCommon StockSEC:0000950170-24-008062:0
11,900 shares@ US$13.1010.9% of flowCommon StockSEC:0000950170-24-002278:0
1,245 shares@ US$10.721.0% of flowCommon StockSEC:0001209191-23-058330:0
96,158 shares0Common StockSEC:0001209191-23-055530:0
1,261 shares@ US$9.412.6% of flowCommon StockSEC:0001209191-23-050173:0
1,266 shares@ US$10.410.9% of flowCommon StockSEC:0001209191-23-049360:0
1,000 shares@ US$13.000.9% of flowCommon StockSEC:0001209191-23-037167:0
1,000 shares@ US$13.000.9% of flowCommon StockSEC:0001209191-23-018981:0
10,000 shares@ US$0.730.5% of flowCommon StockSEC:0001209191-23-004345:0
30,150 shares@ US$11.5725.2% of flowCommon StockSEC:0001209191-23-003013:0
40,000 shares0Common StockSEC:0001209191-22-060972:0
1,246 shares@ US$13.701.3% of flowCommon StockSEC:0001209191-22-050891:0
494 shares@ US$14.050.5% of flowCommon StockSEC:0001209191-22-050122:0
504 shares@ US$4.950.2% of flowCommon StockSEC:0001209191-22-037150:0
481 shares@ US$8.730.3% of flowCommon StockSEC:0001209191-22-018536:0
25 of 27 declarations
